# The Cooper Companies, Inc. Common Stock (COO) — Stock CV

The Cooper Companies, Inc. is a $10.3B healthcare company. Revenue grew 4.7% over the last year, it keeps 13¢ of every dollar of sales as profit, and its net debt equals ~3.5 years of free cash flow. It trades at 18.1× earnings — in the cheapest third of its own history.

> CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical.

## Identity

- **Ticker**: COO
- **Sector**: Healthcare
- **Industry**: Ophthalmic Goods
- **Headquarters**: SAN RAMON, CA
- **Employees**: 15 000
- **Website**: https://www.coopercos.com
- **Market cap**: $10.3B
- **Last price**: $54.37
- **Financial profile**: Strained

## Vitals (TTM)

- **Revenue**: $4.24B
- **Net income**: $570M
- **Free cash flow**: $678M
- **Net debt**: $2.39B
- **P/E**: 18.1
- **Revenue growth (YoY)**: 4.7%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 77 |
| Growth | 49 |
| Profitability | 42 |
| Health | 42 |
| Quality | 90 |
| Moat | 68 |

## Qualifications (beginner checklist) — 8 of 11 passed

- [x] Revenue growing — +4.7% YoY
- [x] Profitable — $570M TTM
- [ ] Profit growing — -1.1% YoY
- [x] Generates cash — $678M TTM
- [x] Debt under control — ~3.5y of cash flow to repay
- [x] Established company — $10.3B market cap
- [x] Not printing shares — +0.8% shares over ~5y
- [x] Proven track record — 10/10 profitable years
- [ ] Financially stable — health score 30/100
- [ ] Pays a dividend — none
- [x] Valuation not extreme — P/E 18.1

## Experience (career milestones)

- **Q3 2026** — 5 open-market insider purchases: ~35K shares bought by insiders
- **2022** — CooperSurgical acquired Cook Medical's reproductive health business for $875 million
- **FY2021** — Best year on record: $2.94B net income
- **2021** — A month later, in March, the company acquired Safe Obstetric Systems
- **FY2016** — Profitable every year on record: 10 consecutive profitable years in our data
- **FY2016** — Revenue already above $1B: $1.97B in first reported year
- **FY2016** — Positive free cash flow every year since: 10-year streak
- **2005** — Ocular Sciences Inc. was acquired by CooperVision in 2005
- **2003** — Three years later, it was further restructured into three business units: CooperVision, CooperSurgical and…
- **1990** — It became a business unit in 1990 and its focus includes women's health and fertility
- **1987** — The company was renamed The Cooper Companies in 1987
- **1980** — Cooper Laboratories reorganized into three business groups: CooperVision, CooperCare and CooperBiomedical
- **1967** — Its name was changed to Cooper Laboratories Inc. in 1967, and entered the contact lens business when it acquired…
- **1961** — The company was renamed to Cooper, Tinsley Laboratories, Inc. in 1961

## Strengths

- High gross margin (65.9%)
- Strong cash conversion — FCF is 16.0% of revenue
- Interest covered 6.2× by operating earnings

## Watch-outs

- None stand out in the data.

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $2.92B | $2.94B | $524M |
| FY2022 | $3.31B | $386M | $450M |
| FY2023 | $3.59B | $294M | $215M |
| FY2024 | $3.90B | $392M | $288M |
| FY2025 | $4.09B | $375M | $434M |

---

Source: https://stockcv.com/COO — derived from company filings; may be delayed or incomplete. Information, not investment advice.